Biotechnology firm Transgene Biotek has received patent in the US for its novel drug to be developed for treatment of Hepato-cellular cancer (HCC) the most common liver cancer.
"This granting of a USA patent is a significant step in moving ahead with the development of this novel drug," Transgene Biotek said in a filing to the BSE (Bombay Stock Exchange).
The company's novel molecule miRNA 101 for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed, it added.
HCC is the most common primary liver cancer, accounting to roughly 90% of this class of malignancy, with poor prognosis due to its ability to rapidly spread, Transgene Biotek said.
The company's current product portfolio covers segments such as oncology, auto-immunity, drug delivery and bio-generics.
Shares of Transgene Biotek closed 4.90% up at Rs 2.57 per scrip on the BSE.